다른 서비스와 비교했을 때 TAK 의 PE 비율은 어느 정도인가요?

TAK은 Price-To-Earnings 비율(22.8x)을 기준으로 볼 때 동종 업체의 평균(20x)과 비교했을 때 비쌉니다.

TAK 의 PE 비율은 US Pharmaceuticals 업계의 다른 회사와 어떻게 비교됩니까?

TAK 은 US Pharmaceuticals 과 비교하여 Price-To-Earnings 비율( 22.8 x)을 기준으로 비용이 많이 듭니다. Pharmaceuticals 업계 평균( 19.4 x).

TAK 의 PE 비율과 공정 PE 비율은 어떻게 되나요? 회사의 예상 수익 성장률, 이익 마진 및 기타 위험 요소를 고려한 예상 PE 비율입니다.

TAK 은 예상 22.8 Price-To-Earnings Price-To-Earnings ( 29.7 x).

미래 현금 흐름을 볼 때 TAK 의 공정 가격은 얼마인가요? 이 추정에는 할인된 현금흐름 모델을 사용합니다.

TAK ( $13.92 )는 당사 추정치인 [[공정 가치]]( $33.88 )

애널리스트의 12개월 전망은 무엇이며 컨센서스 목표가에 대한 통계적 신뢰도가 있나요?

가격 예측을 표시하기에는 데이터가 부족합니다.

Takeda Pharmaceutical (NYSE:TAK) - 주가, 뉴스 및 분석

TAK 주식 개요

다케다제약은 일본 및 해외에서 의약품의 연구, 개발, 제조, 마케팅 및 아웃라이센싱 사업을 하고 있습니다. 자세한 내용

TAK 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	1/6
과거 실적	3/6
재무 상태	3/6
배당금	5/6

보상

공정 가치 추정치보다 낮은 58.9% 에서 거래

수익은 매년 12.17% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 10.3% 증가했습니다.

위험 분석

부채는 영업현금흐름으로 충분히 감당되지 않습니다.

재무 결과에 영향을 미치는 대규모 일회성 항목

4.69% 의 배당금은 수익으로 잘 충당되지 않습니다.

Takeda Pharmaceutical Company Limited 경쟁사

Zoetis

NYSE:ZTS

US$79.8b

Royalty Pharma

NasdaqGS:RPRX

US$15.6b

Jazz Pharmaceuticals

NasdaqGS:JAZZ

US$7.4b

Merck

NYSE:MRK

US$254.5b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Takeda Pharmaceutical
과거 주가
현재 주가	JP¥13.92
52주 최고치	JP¥15.08
52주 최저치	JP¥12.58
베타	0.47
11개월 변경	-0.29%
3개월 변경 사항	-7.08%
1년 변경 사항	-0.36%
33년 변화	0.43%
5년 변화	-31.26%
IPO 이후 변화	-34.49%

최근 뉴스 및 업데이트

Takeda Pharmaceuticals: An Interesting Option For Income Investors

Oct 07

Recent updates

Takeda Pharmaceuticals: An Interesting Option For Income Investors

Oct 07

Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk

Jun 06

주주 수익률

	TAK	US Pharmaceuticals	US 마켓
7D	3.6%	0.8%	0.4%
1Y	-0.4%	12.1%	32.3%

수익률 대 산업: TAK 지난 1년 동안 12.1 %를 반환한 US Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: TAK 지난 1년 동안 32.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is TAK's price volatile compared to industry and market?
TAK volatility
TAK Average Weekly Movement	2.1%
Pharmaceuticals Industry Average Movement	10.1%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

안정적인 주가: TAK 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: TAK 의 주간 변동성( 2% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1781	49,281	Christophe Weber	www.takeda.com

다케다제약은 일본 및 국제적으로 의약품의 연구, 개발, 제조, 마케팅 및 아웃라이센싱을 하고 있습니다. 위장병학, 희귀 질환, 혈장 유래 치료법, 면역학, 종양학, 신경과학 분야의 의약품을 제공합니다. 엔티비오, 가텍스/리베스티브, 타케캡/보신티, 에오힐리아, 알로피셀, 덱실란트, 판토록/컨트롤록, 아디노베이트/아디노비, 페이바, 리콤비네이트, 헤모필/이뮤네이트/이뮤닌, 타크로, 리브텐시티, 애즈진마 브랜드로 제품을 공급하고 있습니다, 엘라프라제, 레플라갈, 애드베이트, 플렉부민, 브이프리브, 감마가드 리퀴드/키오빅, 힉비아, 큐비트루, 엑스케이티비, 프루자클라, 닌라로, 벨케이드, 아질바-F, 로트리가, 아이클루시그, 류플린/에난톤, 애드세트리스, 바이반스/엘반스, 트린텔릭스, 큐덴가 및 알룬브릭 브랜드가 있습니다.

Takeda Pharmaceutical Company Limited 기본 사항 요약

Takeda Pharmaceutical 의 수익과 매출은 시가총액과 어떻게 비교하나요?
TAK 기본 통계
시가총액	US$44.29b
수익(TTM)	US$1.94b
수익(TTM)	US$30.42b

22.8x

P/E 비율

1.5x

P/S 비율

TAK 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
TAK 손익 계산서(TTM)
수익	JP¥4.55t
수익 비용	JP¥1.55t
총 이익	JP¥3.00t
기타 비용	JP¥2.71t
수익	JP¥290.00b

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

Jan 30, 2025

주당 순이익(EPS)	182.94
총 마진	65.95%
순이익 마진	6.38%
부채/자본 비율	73.0%

TAK 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

배당금

4.7%

현재 배당 수익률

104%

지급 비율

TAK 주식 개요

보상

위험 분석

Takeda Pharmaceutical Company Limited 경쟁사

NYSE:ZTS

US$79.8b

NasdaqGS:RPRX

US$15.6b

NasdaqGS:JAZZ

US$7.4b

NYSE:MRK

US$254.5b

가격 내역 및 성능

최근 뉴스 및 업데이트

Takeda Pharmaceutical Company Limited to Report Q3, 2025 Results on Jan 30, 2025

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Pharmaceuticals: An Interesting Option For Income Investors

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Recent updates

Takeda Pharmaceutical Company Limited to Report Q3, 2025 Results on Jan 30, 2025

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Pharmaceuticals: An Interesting Option For Income Investors

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda: Upside Case Strengthening, Looking To 15x Earnings

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Takeda Pharmaceutical Company Limited Proposes Dividend

Takeda Pharmaceutical Company Limited to Report Q2, 2024 Results on Oct 26, 2023

Takeda Announces S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year 2023